Pulmonx Q4 2023 Earnings Report $8.96 +0.18 (+2.05%) As of 02/21/2025 04:00 PM Eastern Earnings HistoryForecast Pulmonx EPS ResultsActual EPS-$0.36Consensus EPS -$0.38Beat/MissBeat by +$0.02One Year Ago EPS-$0.38Pulmonx Revenue ResultsActual Revenue$19.30 millionExpected Revenue$18.24 millionBeat/MissBeat by +$1.06 millionYoY Revenue Growth+25.30%Pulmonx Announcement DetailsQuarterQ4 2023Date2/21/2024TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptPress ReleaseLUNG Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Pulmonx Earnings HeadlinesPulmonx Corporation: Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial ResultsFebruary 21 at 4:43 AM | finanznachrichten.dePulmonx (LUNG) Gets a Buy from Piper SandlerFebruary 21 at 4:43 AM | markets.businessinsider.comThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…February 23, 2025 | Crypto 101 Media (Ad)Pulmonx projects 16%-18% constant currency growth for 2025 with key initiatives scalingFebruary 20 at 4:13 PM | seekingalpha.comPulmonx (LUNG) Receives a Buy from Stifel NicolausFebruary 20 at 4:13 PM | markets.businessinsider.comPulmonx Corporation (LUNG) Q4 2024 Earnings Call TranscriptFebruary 19, 2025 | seekingalpha.comSee More Pulmonx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pulmonx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pulmonx and other key companies, straight to your email. Email Address About PulmonxPulmonx (NASDAQ:LUNG), a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.View Pulmonx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)ONEOK (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Home Depot (2/25/2025)Public Storage (2/25/2025)Sempra (2/25/2025)NVIDIA (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
